Ignacio Diaz EmergpharmaNov 15, 20196 minCommercial strategies for biosimilars: Any sense to register several brands? Biosimilars have traditionally been seen by large pharmaceutical companies as a threat to their most profitable products and the priority...
Ignacio Diaz EmergpharmaOct 11, 20194 minOncology market in Germany to grow more than 20%. Can the sistem support it?Preliminary results of the First Report on the German market of oncological medicines 2016-2018 performed by Emergpharma show some intere...
Ignacio Diaz EmergpharmaOct 11, 20196 minAnti TNF biosimilars of infliximab and etanercept got 63% and 44% of Top 5 EU in less than 3 yearsBiosimilar penetration differs among countries in Top 5 EU markets, but the trend is to a faster and deeper curve.